About the project

We aim to design a personalized enhanced and combined nano-immunotherapeutic approach to treat lung cancer patients, based on the use of proprietary polymeric nanoparticles encapsulating nucleic acids as active principles.

These nucleic acids will:

a) act as antigens to immunize patients against tumor antigens and achieve the self-killing of tumor cells (mRNA cancer vaccination); and

b) immunomodulate the TME by silencing key immunosuppressor genes (targeted therapy).

Partner
members

The project is carried out with partners from different fields, building a multidisciplinary and transversal consortium. Learn more about the members and their research profiles.

Contact

If you have questions about the project or need further information, you can leave your personal information so we can contact you.